TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily signed informed consent for participation in this clinical study;~* 18 to 45 years old inclusive, male and female;~* Diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat;~* Onset of first symptoms of the uncomplicated acute infectious and inflammatory diseases of the pharynx (pharyngitis and/or tonsillitis) less than 48 hours prior to inclusion into the study; Baseline TSS score (Tonsillopharyngitis Severity Score) ≥ 5 (total score);~* Body temperature 37,5 C (axillary).~Exclusion Criteria:~* Use of analgesics within \<12 hours prior to the study start or/and inability to cancel them during the study;~* Use of antibiotics within \<48 hours prior to the study start or/and inability to cancel them during the study;~* Use of local therapy (sprays, rinses, lozenges) to pharynx within \<12 hours before study start or/and inability to cancel them, besides study medications;~* Use systemic or inhaled corticosteroids within ≤1 months prior to the study start and planned therapy of them during the study (besides skin means);~* Presence of symptoms of primary bacterial pharyngitis or secondary bacterial infection (including fever over 37,5 ° C, the presence of purulent raids in the throat, severe intoxication, leukocytosis, neutrophilia, shift leukocyte left (increasing the percentage of neutrophils sticks appearance younger forms of neutrophils), increased ESR 30 mm/hr).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Angal S (Arm A) (Type: EXPERIMENTAL): Patients received Angal S, topical spray \[Menthol\], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
- ANTI-ANGIN® FORMULA (Arm B) (Type: ACTIVE_COMPARATOR): Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients presenting~a. to the neurologist for evaluation of stroke or TIA (Symptomatic) with: i. Symptomatic patients with plaque ≥70% in at least one carotid artery that would be implicated as the source of embolus responsible for the stroke/TIA. b. or to the vascular surgeon for CEA (Asymptomatic) with: i. asymptomatic patients with a luminal stenosis of ≥70% in at least one carotid artery (stable plaque) referred for CEA ii. age-matched by deciles to symptomatic patients~Exclusion Criteria:~1. stroke due to atrial fibrillation,~2. preexisting carotid stents in the artery of interest,~3. renal dysfunction defined as glomerular filtration rate (GFR) \<40ml/min,~4. allergy to gadolinium based contrast agents,~5. Volunteers who have had four or more prior previous gadolinium contrast scans~6. metal implants incompatible with MRI or other condition that prohibits MRI,~7. pregnancy,~8. inability to provide informed consent and~9. age ≤18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [F-18] RDG-K5 (Type: EXPERIMENTAL): PET/CT Imaging with administration of \[F-18\] RGD-K5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females at least 18 years old at screening~2. Females must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control~3. Chronic hepatitis C, genotype 1 infection~4. Males must be surgically sterile or agree to practice acceptable forms of birth control~5. Screening laboratory result indicating HCV genotype 1 infection~Exclusion Criteria:~1. Use of contraindicated medications within 2 weeks of dosing~2. Abnormal laboratory tests~3. Current or past clinical evidence of Child-Pugh B or C classification or history of liver decompensation~4. Confirmed presence of hepatocellular carcinoma~5. History of solid organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV) (Type: EXPERIMENTAL): Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cognitive-Behavioural and Hypnotic Treatment of Chronic Primary Insomnia Among the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 55 years or older~* fulfilment of the DMS-IV criteria for insomnia, including difficulties initiating sleep, maintaining sleep, and/or early morning awakenings with no ability of return to sleep~* duration of at least 3 months~* complaints of impaired daytime functioning.~Exclusion Criteria:~* use of hypnotic medication the last 4 weeks before project start~* use of antidepressive or antipsychotic medications~* signs of dementia or other serious cognitive impairment defined by a score under 25 on the Mini-Mental State Examination~* presence of a major depressive disorder or other severe mental disorder as identified by a clinical assessment based on The Structured Clinical Interview for DSM-IV (SCID-I)~* presence of sleep apnea defined as (A/H index \> 15) or periodic limb movements during sleep (PLM index with arousal \> 15),~* working nightshifts and unable or unwilling to discontinue this work pattern,~* willingness or inability to stop taking sleep medication before start~* having a serious somatic conditions preventing further participation

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A primary diagnosis of PTSD \[Post Traumatic Stress Disorder, according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders)\] with the primary traumatic event occurring ≥12 months prior to screening.~* PCL-5 (PTSD Checklist for DSM-5) ≥38 at screening.~* CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) total score ≥30 at screening.~Exclusion Criteria:~* Complex PTSD.~* Trauma focused psychotherapies.~* Primary traumatic event occurred prior to 2001.~* Primary traumatic event was followed by further major traumatic life episodes.~* Other psychiatric disorders that is the primary focus of treatment or followed/worsened since exposure to the trauma (except for major depressive disorder or anxiety disorders that followed exposure to the trauma or an anxiety disorder that showed a worsening after trauma)~* Current use of medications with primarily central nervous system activities~* Other clinically significant medical histories that may interfere with completing the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- NYX-783 Low Dose (10 mg QD) (Type: EXPERIMENTAL): None
- NYX-783 High Dose (50 mg QD) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Maxillar bone cyst with diameter larger than 2 cm and smaller than 4 cm~* Understanding and written acceptance of assay conditions~* Informed written consent of the patient for assay and for surgery~* In women, negative pregnancy test at t=0~* In women, compromise of using anticonceptive methods during the study~Exclusion Criteria:~* Age under 18 or over 65~* Incapacity or legal dependence~* Pregnancy, lactancy, or enrollment in fertility programs~* Previous or concomitant oncological processes.~* Positive serology for HIV-1 orHIV-2, Hepatitis B (HBsAg, Anti-HCV-Ab) or Hepatitis C (Anti-HCV-Ab).~* Immunocompromised patients~* Systemic disease with potential effects on bone metabolism~* Congenital or acquired maxillofacial malformation~* Patients with prescription of drugs acting on bone metabolism, suc as glucocorticoids and bisphosphonates~* Active or recent infection of the cyst~* Recidive of the cyst (previous surgery)~* Participation in other trials or studies in the last 3 months.~* Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MSV treatment (Type: EXPERIMENTAL): MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Text Reminders to Immunize in a Managed Care Organization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 11-\<18 years~* Member of MCO for \>6 months~* Opted in to receive texted reminders from MCO~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Text-based reminder for HPV vaccine/WCC (Type: EXPERIMENTAL): Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
- Control arm (Type: ACTIVE_COMPARATOR): Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ACute and Chronic Effects of Saxagliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Social security affiliation~* Persons without TUTORSHIP that can freely agree to participate to the study~* Age between 18 to 70 years~* Impaired glucose tolerance diagnosed during the previous month.~Exclusion criteria:~* Pregnancy~* Breast feeding~* Diabetes~* No contraception~* Body Mass Index \> 45 kg/m²~* Arterial blood pressure \> 160/110 mmHg~* Creatinine clearance \< 60 ml/min~* Severe hepatocellular insufficiency~* Chronic respiratory disease~* Anaemia (Hemoglobin \< 10 g/dl)~* Peripheral arterial occlusive disease~* Heart failure~* Cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: EXPERIMENTAL): Saxagliptin 5 mg (tablet) at BREAKFEAST
- placebo pill (Type: PLACEBO_COMPARATOR): at BREAKFEAST

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18-60 years old~* Patients with systolic hypertension who met the 24 hour Ambulatory Blood Pressure Monitoring (ABPM) criteria (ABPM mean daytime Systolic Blood Pressure (SBP) \>= 135 mmHg and \< 160 mmHg)~Exclusion Criteria:~* Overt heart failure (HF) or a history of heart failure within preceding 6 months.~* Unstable angina pectoris.~* Type 1 or Type 2 diabetes mellitus or abnormal hemoglobin A1c(HbA1c)~* Body mass index (BMI) \> 30 kg/m2~* Subjects taking more than 2 antihypertensive medications.~* Use of other investigational drugs within 30 days of the time of enrollment~* Use of Tamsulosin hydrochloride and other alpha blockers.~* Use of Antiarrhythmic drugs, including digoxin.~* History of MI or cardiovascular attack (CVA) within the preceding 6 months.~* History of malignancy of any organ system, treated or untreated, within the past 5 years with the exception of localized basal cell carcinoma of the skin~* Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Diet Sequence Low/High Sodium (Type: EXPERIMENTAL): Patients on low sodium diet ( \<= 100 mmol/day) for the first 4 weeks and high sodium (\>= 200 mmol/day) diet for the next 4 weeks. \[with Aliskiren 300 mg\]
- Diet Sequence High/Low Sodium (Type: EXPERIMENTAL): Patients on high sodium (\>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( \<= 100 mmol/day) for the next 4 weeks. \[with Aliskiren 300 mg\]

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Popliteal Block for Postoperative Pain in Knee-ankle Soft Tissue Surgery in Cerebral Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with cerebral palsy~* Scheduled for knee and ankle surgery~Exclusion Criteria:~* Autonomic neuropathy~* Medication with anticholinergic drugs~* Continuous infusion of vasoactive drugs

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- popliteal block (Type: ACTIVE_COMPARATOR): Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
- Plaster cover (Type: SHAM_COMPARATOR): Only plaster cover will be applied without nerve block for sham procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Ankle Exoskeleton Assistance for Walking Across the Life Span

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be able to walk for 60 minutes in a 90-minute time frame.~* Subjects are apparently free of cardiovascular, metabolic, and renal disease, which includes no signs or symptoms suggestive of cardiovascular, metabolic or renal disease.~* Subjects have no current musculoskeletal injury.~* Subjects need to be either 18-45 or 65+ years old.~These criteria meet the American College of Sports Medicine's 2015 guidelines for participant health screening prior to joining a moderate or moderate-to-vigorous exercise protocol. (Riebe et al., 2015).~Exclusion Criteria:~* Have dementia or an inability to give informed consent~* Have a musculoskeletal injury or feel pain while walking~* Have a history of dizziness and/or balance problems~* Have cardiovascular, heart, metabolic, or renal disease, or respiratory problems~* Smoke cigarettes~* Asthma~* Feel pain or discomfort in the chest, neck, jaw, arms during rest or exercise~* Have orthopnea or paroxysmal nocturnal dyspnea~* Have ankle edema~* Have palpitations or tachycardia~* Have a heart murmur~* Have had a heart attack~* Have diabetes~* Have a pace maker~* Have unusual shortness of breath with usual activities~* Are \<18 or 46-64 years of age~* Do not speak or understand English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Young Adult Exoskeleton Users (Type: EXPERIMENTAL): Study participants who are 18-45 year old.
- Older Adult Exoskeleton Users (Type: EXPERIMENTAL): Study participants who are greater than 65 years of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of a Reduced Primary Schedule for Pneumococcal Conjugate Vaccine in UK Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent by parent/guardian for receipt of study vaccines and for blood samples~* Age at first dose: Infants 7-11 weeks; toddlers 12-18 months~Exclusion Criteria:~* Previous bacteriologically confirmed pneumococcal or meningococcal disease~* Contraindications for pneumococcal, meningococcal, Hib, DTP, MMR immunisations as listed in the UK handbook, Immunisation Against Infectious Disease Edition 1996.~* Language difficulty in parents sufficient to preclude adequate comprehension of the information sheet, consent form and study nurses' explanation of the study~* Children participating in any other clinical trial~* Immunocompromised~* Acute systemic illness or fever \> 38C on day of vaccination - deferral

- Gender: ALL
- Minimum Age: 7 Weeks
- Maximum Age: 18 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects who have volunteered and consented to participate in the study.~2. Subjects who have no contraindication to taking high dose, oral prednisone or Acthar.~3. Male or Female subjects age 18 or greater years of age.~4. Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) based on 2010 McDonald Criteria.~5. Subjects without an active infection (Note: If a patient is found to have an uncomplicated UTI and agrees to start on appropriate antibiotic treatment, they can continue in the study).~6. Subjects who are experiencing a protocol defined MS relapse within two weeks of relapse onset.~7. Subjects who are able and willing to sign a consent form.~Exclusion Criteria:~1. Subjects who are less than 18 years of age.~2. Subjects with any contraindication to taking Acthar.~3. Subjects with an active infection other than an uncomplicated urinary tract infection (UTI) (subjects determined to have a UTI who agree to be treated with appropriate antibiotics will not be excluded).~4. Subjects with an immune deficiency.~5. Subjects with a history of any of the following conditions: gastrointestinal ulcers, diabetes mellitus, gestational diabetes, malignant hypertension or steroid induced psychosis.~6. Subjects who are pregnant or breastfeeding.~7. Subjects who are unable or unwilling to sign consent form.~8. Patient is unable or unwilling to participate in phone and clinic follow up.~9. Other factors that in the opinion of the Principal Investigator would exclude the subject from participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single arm (Type: EXPERIMENTAL): Acthar 80 units subcutaneously for five consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete